We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




1 Hour Direct-From-Blood Test Detects 95% Of Pathogens Associated with Bloodstream Infections

By LabMedica International staff writers
Posted on 11 Dec 2024

Early detection is crucial for treating a variety of infections, particularly sepsis. More...

Sepsis is responsible for one in three hospital deaths in the U.S., and septic shock has a global mortality rate of 30-40%. However, early diagnosis remains difficult due to the non-specific and often subtle symptoms. Currently, the standard method for diagnosing sepsis involves complex blood culture tests, which can take several days to provide results. This method, over 40 years old, is limited to identifying 'viable' organisms, often overlooking a wide array of microbial markers present in the blood. Now, a groundbreaking one-hour test can detect 95% of pathogens linked to bloodstream infections (BSIs) that could lead to sepsis, along with specific genetic markers for antimicrobial resistance (AMR).

deepull’s (Barcelona, Spain) UllCORE BSI Test and UllCore system offer 50 reportable results, identifying pathogens and antibiotic resistance markers directly from blood within about one hour. This real-time multiplex PCR system extracts microbial DNA from 8 mL of whole blood, bypassing the slow blood culture process. The assay covers a broad range of bacterial targets, fungi, and genetic determinants of antibiotic resistance. UllCORE’s rapid results and high sensitivity empower clinicians to make better-informed decisions, minimizing the risks of over- and under-treatment with antibiotics and contributing to efforts to combat antimicrobial resistance in hospitals. While focused on sepsis, deepull envisions its system as useful for diagnosing various other acute infections. The company has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the UllCORE BSI Test.

“We are thrilled to receive breakthrough designation from the FDA,” said Jordi Carrera, Chief Executive Officer and Co-Founder of deepull. “Providing life-saving results for patients suspected of serious infection in one hour represents a significant advantage over current standard of care blood culture. Faster pathogen identification and AMR testing will provide clinicians with a powerful tool to more quickly and accurately tailor antimicrobial therapy, which could lead to faster patient recovery, shorter length of stay, and reduced morbidity and mortality.”

Related Links:
deepull


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.